> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Establishment Labs Posts Its First Positive Free Cash Flow Quarter As U.S. Sales Climb 119%
- URL: https://www.bullished.co/establishment-labs-posts-its-first-positive-free-cash-flow-quarter-as-u-s-sales-climb-119-285becb2/
- Published: 2026-10-29T12:39:11.000Z
- Updated: 2026-10-29T12:39:10.000Z
- Description: The breast-implant maker raised its 2026 revenue outlook to more than $274 million, though it still lost $10.7 million in the quarter.
- Author: Matteo Parrino
- Tags: SEC Filings, ESTA, Industry: Healthcare

[Establishment Labs](https://www.bullished.co/tag/esta/), which makes Motiva silicone breast implants, generated [$5.1 million of free cash flow](https://www.sec.gov/Archives/edgar/data/0001688757/000168875726000056/estaerq32026-ex991.htm?ref=bullished.co) in the third quarter, the first positive quarter in its history, the company said Thursday. Revenue rose 33.9% to $72.0 million, and the company raised its full-year revenue forecast.

## Cash turns positive, losses persist

Operating activities produced [about $7.7 million](https://www.businesswire.com/news/home/20261029198419/en/Establishment-Labs-Reports-Third-Quarter-2026-Financial-Results?ref=bullished.co) of cash in the quarter, against cash used in the year-earlier period. Free cash flow, which the company defines as operating cash minus spending on equipment and certain intangibles, came to $5.1 million.

The cash result is a quarterly one. For the first nine months of 2026, operating activities still used $13.2 million, and free cash flow was negative $21.4 million.

The net loss narrowed to [$10.7 million](https://www.businesswire.com/news/home/20261029198419/en/Establishment-Labs-Reports-Third-Quarter-2026-Financial-Results?ref=bullished.co), or $0.35 per share, from $11.1 million, or $0.38, a year earlier. Adjusted EBITDA, which strips out interest, taxes, depreciation and items such as stock pay, litigation and restructuring, rose to $6.4 million from $1.2 million. Interest expense was $6.8 million in the quarter. Cash stood at $75.8 million on September 30.

## U.S. sales more than double

U.S. revenue climbed 119.0% to $26.0 million, while sales outside the U.S. rose 9.7% to $46.0 million. Minimally invasive revenue, from newer procedures that use the company's smaller-incision products, grew 124.0% to about $9 million.

Standard gross margin slipped to 69.1% from 70.1%, including $1.3 million of inventory charges tied to restructuring. Excluding those charges, adjusted gross margin was 70.8%, up 70 basis points (0.70 percentage points). The company said stronger-than-anticipated sales to distributors outside the U.S. came at lower margins.

Adjusted operating expenses were $49.6 million, or 68.8% of revenue, against 77.6% a year earlier. Standard operating expenses rose to $52.3 million from $41.7 million.

## Outlook, 2027 target and FDA review

Establishment Labs now expects 2026 revenue of more than $274 million, up from earlier guidance of $269 million to $271 million. It forecasts adjusted gross margin of about 70.7% and positive adjusted EBITDA for the year. Adjusted operating expenses of $195 million to $200 million are unchanged.

CEO Peter Caldini said the company expects 2027 growth of 25% and positive cash flow. The company said its FDA review of Motiva for breast reconstruction is progressing in line with expectations. It also received FDA approval for additional smaller Motiva sizes and has more than 2,100 U.S. accounts, with more than 400 surgeons trained on its Preservé technology, according to the company release.

The company, which sells Motiva in over 100 countries, mostly through exclusive distributors, carried a $267.8 million note payable at quarter's end, according to its [8-K](https://www.sec.gov/Archives/edgar/data/0001688757/000168875726000056/esta-20261029.htm?ref=bullished.co).

The company hosted its earnings call at 8:30 a.m. Eastern on Thursday, and it says 2027 should bring 25% growth and positive cash flow.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — ESTABLISHMENT LABS HOLDINGS INC. (ESTA)](https://www.sec.gov/Archives/edgar/data/0001688757/000168875726000056/esta-20261029.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit estaerq32026-ex991.htm — ESTABLISHMENT LABS HOLDINGS INC. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001688757/000168875726000056/estaerq32026-ex991.htm?ref=bullished.co) — SEC EDGAR
- [Establishment Labs® Reports Third Quarter 2026 Financial Results](https://www.businesswire.com/news/home/20261029198419/en/Establishment-Labs-Reports-Third-Quarter-2026-Financial-Results?ref=bullished.co) — businesswire.com

### More on Establishment Labs

- [Establishment Labs Extends NuSil Silicone Supply Deal Five Years, To December 31, 2031](https://www.bullished.co/establishment-labs-extends-nusil-silicone-supply-deal-five-years-to-december-31-2031-0465bed4/)

[All Establishment Labs (ESTA) coverage →](https://www.bullished.co/tag/esta/)